Loading
Old version — revision 1
This is a fixed snapshot of Synchron, saved by Import as part of the initial corpus import. It is not edited and it is not updated; the article may have changed since.
Edit summary: Initial import of content/synchron.md — the filesystem corpus, unchanged. Not an edit.
A neurotechnology company developing an endovascular brain–computer interface implanted through a blood vessel rather than by opening the skull.
Synchron is a neurotechnology company developing the Stentrode, a Brain–computer interface built into a vascular stent and delivered to a vein on the surface of the motor cortex through the jugular, avoiding craniotomy entirely. Founded in Melbourne in 2012 and now headquartered in New York, it began implanting patients in Australia in 2019 and in the United States in 2022, and it has pursued a deliberately low-bandwidth strategy in contrast to competitors chasing channel count.
The company's strategic premise is that the binding constraint on BCI deployment is not the number of neurons recorded but the willingness of surgeons, regulators and patients to accept an implant. Open-skull electrode arrays require neurosurgery, carry infection and haemorrhage risk, and are performed at a small number of centres. Endovascular delivery is a procedure that interventional neuroradiologists already perform thousands of times a year for stroke and aneurysm, using equipment that already exists in most large hospitals. The argument is explicitly modelled on the diffusion of the Cochlear implant and of Deep brain stimulation, both of which reached large patient populations only once the implantation procedure became routine.
The cost of that choice is signal. The Stentrode carries sixteen electrodes sitting inside a vessel wall, separated from cortex by the vessel and by tissue, and records local field potentials rather than single-unit activity. It cannot approach the information rate of a penetrating array. Synchron's position is that a small, reliable set of control signals is sufficient for the applications that matter first — switch control, cursor movement, and communication for people with severe paralysis.
Thomas Oxley, a neurologist, and Nicholas Opie, a biomedical engineer, developed the endovascular approach at the University of Melbourne with support from Australian and United States defence research funding. The founding insight was that veins run close to the cortical surface, that stents are routinely delivered to them, and that a stent could carry electrodes and become endothelialized into the vessel wall over weeks, stabilizing the recording. The group's 2016 report of chronic cortical recordings from a stent-mounted array in freely moving sheep established that the approach could work at all.1
The SWITCH trial implanted the device in four Australian patients with severe paralysis, mostly from amyotrophic lateral sclerosis. The first-in-human report described patients using the system for digital device control at home,2 and a subsequent safety analysis found no device-related serious adverse events and no vessel occlusion at twelve months.3 Synchron then received a United States investigational device exemption and began the COMMAND early feasibility study, implanting its first American patient in 2022 at Mount Sinai; COMMAND enrolled a small cohort across several centres and has been reported as meeting its primary safety endpoint.
The device is a self-expanding nitinol stent with electrodes mounted on its struts. It is delivered by catheter through the jugular vein into the superior sagittal sinus, the large vein running along the midline above the motor cortex, and deployed so that the electrodes press against the vessel wall adjacent to motor cortex, whose leg representation lies nearest the midline. Over several weeks the stent endothelializes, becoming incorporated into the vessel wall, which both stabilizes it mechanically and, Synchron argues, reduces the chronic foreign-body response that degrades penetrating array signals over years.
A lead runs down the vein to a subclavian transmitter unit implanted in the chest, which powers the array and relays data wirelessly. The architecture is closer to a pacemaker than to a research rig, a design choice shared with most deployed Neuroprosthetics. The system decodes attempted movements — typically of a foot or ankle — into discrete switch events, which are mapped onto interface actions. No stimulation is delivered, so the device provides no sensory feedback and is not a bidirectional interface.
The signal ceiling follows from the recording site: local field potentials rather than the spike trains that Neural decoding work on penetrating arrays exploits, which limits the system to a small number of distinguishable commands and makes the interaction paradigm resemble switch scanning rather than continuous multi-degree-of-freedom control. Stentrode sets out the mechanism in full.
The tradeoff stated plainlyA Utah array records individual neurons and supports high-dimensional control, at the cost of a craniotomy and progressive signal loss from glial scarring. The Stentrode records population activity through a vessel wall and supports a handful of commands, at the cost of no craniotomy and a stable interface. Which is the better device depends entirely on how many patients would accept brain surgery, a question the field has not answered empirically.
Synchron has raised venture funding from investors including ARCH Venture Partners, with participation reported from vehicles associated with Jeff Bezos and Bill Gates. It has pursued integration partnerships rather than building its own application layer: a demonstration of Amazon Alexa control, and, in 2025, participation in Apple's addition of a native brain–computer interface input protocol to its accessibility framework — the first time a major consumer platform treated neural input as a first-class modality alongside touch and switch control. A separate collaboration with NVIDIA concerns machine-learning models for decoding, using the accumulated recordings from its trial participants.
The platform strategy matters more than it appears. A BCI that presents itself to an operating system as a standard input device inherits every application already written for accessibility, which removes a substantial part of the software problem from the company's own scope.
Clinical reception has been favourable on safety, which is the metric an early feasibility study is designed to address. Independent commentators have noted that endovascular delivery genuinely lowers the barrier to implantation and that the reported vessel patency results are the most important finding, since thrombosis in a major cerebral vein would be a catastrophic failure mode.
Criticism concentrates on capability. Sixteen channels of field potential cannot support the speech decoding results that electrocorticographic and penetrating arrays have produced, and cannot approach the cursor performance demonstrated by BrainGate participants. Some researchers argue that the company's approach solves the wrong constraint: that patients with locked-in syndrome will accept a craniotomy, and that the value of a BCI scales steeply with bandwidth. Synchron's counter is that the field has produced two decades of impressive results in a few dozen research participants and almost no deployed devices, and that reaching many patients requires a procedure that ordinary hospitals can perform.
The comparison with Neuralink is unavoidable and largely unhelpful, since the two are pursuing different points on the same tradeoff curve. Neuralink's robot-inserted thread arrays record far more channels and require skull penetration; Synchron's device records far fewer and does not. Both remain in early clinical studies, and neither has an approved product.
The decisive question is whether a pivotal trial can demonstrate benefit against an endpoint a regulator accepts. Early feasibility studies establish safety in a handful of patients; approval requires a defined patient population, a validated outcome measure, and a comparator, none of which the BCI field has settled. Synchron has said it intends to run a larger trial, and the design of that trial will reveal what claim the company believes it can support.
The second question is durability. Endothelialization stabilizes the device but also fixes it permanently in a vessel; explantation has not been demonstrated in humans and the long-term consequences of a foreign body in a major cerebral sinus over decades are unknown.
The third is governance. The Neurorights campaign and the Mental privacy literature both concern who owns neural recordings and what may be inferred from them, and a device that streams cortical signals to a consumer operating system sits directly in the path of that argument. Field potentials from motor cortex are crude by the standards of what laboratory decoding work can extract, which is a weak reassurance rather than a strong one: the history of the field is that inference from neural data consistently outruns what the raw signal appears to contain. Whether the bandwidth ceiling that limits the device also limits the Human–AI merger ambitions that motivate much BCI investment is a question Synchron's own strategy answers in the affirmative, and its competitors dispute.
paperOxley, T.J. et al. "Minimally invasive endovascular stent-electrode array for high-fidelity, chronic recordings of cortical neural activity." Nature Biotechnology, 2016. ↩
paperOxley, T.J. et al. "Motor neuroprosthesis implanted with neurointerventional surgery improves capacity for activities of daily living tasks in severe paralysis: first in-human experience." Journal of NeuroInterventional Surgery, 2021.↩Authored by the company's founders about the trial they designed; a first-in-human report records early use and does not test efficacy.
paperMitchell, P. et al. "Assessment of Safety of a Fully Implanted Endovascular Brain-Computer Interface for Severe Paralysis in 4 Patients: The Stentrode With Thought-Controlled Digital Switch (SWITCH) Study." JAMA Neurology, 2023.↩A four-patient safety series with no comparison group; twelve-month vessel patency is what it establishes, not clinical benefit.